Collegium Pharmaceutical, Inc (COLL)

Name: Collegium Pharmaceutical, Inc (COLL) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name COLLEGIUM PHARMACEUTICAL, INC · CIK 0001267565 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated VA
Fiscal year ends Dec 31

For the year ended 2025-12-31, Collegium Pharmaceutical, Inc reported revenue of $780.57M. Revenue grew 23.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $808.21M.

Key ratios (year ended 2025-12-31)

59.3%

Gross margin

23.0%

Operating margin

8.1%

Net margin

20.8%

Return on year-end equity

23.6%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$808.21M	$780.57M	$631.45M	$566.77M	$463.93M	$276.87M	$310.02M	$296.70M	$280.41M	$28.48M	$1.71M
Cost of Revenue	$323.12M	$317.31M	$254.10M	$240.60M	$254.44M	$126.25M	$130.18M	$193.66M	$165.68M	$2.60M	$213.0K
Gross Profit	$485.09M	$463.26M	$377.34M	$326.17M	$209.49M	$150.62M	$179.84M	$103.04M	$114.74M	$25.88M	$1.50M
R&D Expense	n/a	n/a	$0	$0	$3.98M	$9.45M	$9.77M	$10.34M	$8.66M	$8.57M	$14.95M
Operating Income	$157.44M	$179.64M	$169.90M	$166.96M	$33.32M	$17.63M	$56.23M	-$23.75M	-$20.68M	-$75.45M	-$94.08M
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$731.0K	$1.07M	$594.0K	$655.0K
EBITDA	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-$23.02M	-$19.61M	-$74.85M	-$93.43M
Net Income	$47.91M	$62.87M	$69.19M	$48.16M	-$25.00M	$71.52M	$26.75M	-$22.72M	-$39.13M	-$74.86M	-$94.18M
EPS (Diluted)	n/a	$1.73	$1.86	$1.29	-$0.74	$1.86	$0.76	-$0.68	-$1.19	n/a	n/a
Total Assets	$2.14B	$1.66B	$1.66B	$1.14B	$1.17B	$692.08M	$643.84M	$306.30M	$291.25M	$135.57M	$162.02M
Total Liabilities	$1.82B	$1.36B	$1.43B	$947.88M	$979.29M	$489.15M	$457.81M	$218.87M	$199.66M	$31.49M	$27.11M
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$11.50M	$11.50M	n/a	$4.15M
Shareholders' Equity	$311.91M	$301.68M	$228.84M	$195.43M	$194.84M	$202.93M	$186.03M	$87.43M	$91.58M	$104.08M	$134.91M
Cash & Equivalents	$129.47M	$231.25M	$70.56M	$238.95M	$173.69M	$186.43M	$174.12M	$170.02M	$146.63M	$118.70M	$153.22M
Operating Cash Flow	$329.92M	$329.32M	$204.98M	$274.75M	$124.23M	$103.56M	$93.94M	$27.78M	$169.39M	-$67.02M	-$75.05M
Capital Expenditures	$1.64M	$1.74M	$1.65M	$461.0K	$1.62M	$1.94M	$5.55M	$6.44M	$5.48M	$990.0K	$477.0K
Free Cash Flow	$328.28M	$327.58M	$203.33M	$274.29M	$122.61M	$101.61M	$88.40M	$21.34M	$163.91M	-$68.01M	-$75.53M
Share Repurchases	n/a	$25.10M	$60.02M	$75.00M	$14.06M	$47.86M	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	32.50M	31.71M	31.44M	31.87M	33.85M	33.66M	34.61M	33.68M	33.27M	32.77M	29.36M
Weighted Average Diluted Shares	n/a	39.70M	40.42M	41.79M	33.83M	41.05M	35.15M	33.45M	32.95M	n/a	n/a
EPS (Basic)	n/a	$1.98	$2.14	$1.43	-$0.74	$2.05	$0.78	-$0.68	-$1.19	n/a	-$3.88

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView